Cipla Q1 results preview: Muted US sales to hit revenue YoY. 4 things to watch out for

Cipla's June quarter earnings are anticipated to reveal a mixed performance, with robust India sales partially offsetting challenges in the US generics market. Revenue is expected to increase, while EBITDA margins may decline due to lower US contributions. Investor attention will be directed towards the US business trajectory, pricing dynamics, and the resurgence of India's trade generics segment.